Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Genetic risk of Parkinson disease and progression:: An analysis of 13 longitudinal cohorts.

Iwaki H, Blauwendraat C, Leonard HL, Liu G, Maple-Grødem J, Corvol JC, Pihlstrøm L, van Nimwegen M, Hutten SJ, Nguyen KH, Rick J, Eberly S, Faghri F, Auinger P, Scott KM, Wijeyekoon R, Van Deerlin VM, Hernandez DG, Day-Williams AG, Brice A, Alves G, Noyce AJ, Tysnes OB, Evans JR, Breen DP, Estrada K, Wegel CE, Danjou F, Simon DK, Ravina B, Toft M, Heutink P, Bloem BR, Weintraub D, Barker RA, Williams-Gray CH, van de Warrenburg BP, Van Hilten JJ, Scherzer CR, Singleton AB, Nalls MA.

Neurol Genet. 2019 Jul 9;5(4):e348. doi: 10.1212/NXG.0000000000000348. eCollection 2019 Aug.

2.

Toll-like receptors and their therapeutic potential in Parkinson's disease and α-synucleinopathies.

Kouli A, Horne CB, Williams-Gray CH.

Brain Behav Immun. 2019 Jul 2. pii: S0889-1591(19)30082-0. doi: 10.1016/j.bbi.2019.06.042. [Epub ahead of print] Review.

PMID:
31271873
3.

Inflammation in mild cognitive impairment due to Parkinson's disease, Lewy body disease, and Alzheimer's disease.

King E, O'Brien J, Donaghy P, Williams-Gray CH, Lawson RA, Morris CM, Barnett N, Olsen K, Martin-Ruiz C, Burn D, Yarnall AJ, Taylor JP, Duncan G, Khoo TK, Thomas A.

Int J Geriatr Psychiatry. 2019 Aug;34(8):1244-1250. doi: 10.1002/gps.5124. Epub 2019 May 16.

PMID:
30993722
4.

The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease.

White AJ, Wijeyekoon RS, Scott KM, Gunawardana NP, Hayat S, Solim IH, McMahon HT, Barker RA, Williams-Gray CH.

Front Neurol. 2018 Nov 20;9:946. doi: 10.3389/fneur.2018.00946. eCollection 2018.

5.

Monocyte Function in Parkinson's Disease and the Impact of Autologous Serum on Phagocytosis.

Wijeyekoon RS, Kronenberg-Versteeg D, Scott KM, Hayat S, Jones JL, Clatworthy MR, Floto RA, Barker RA, Williams-Gray CH.

Front Neurol. 2018 Oct 16;9:870. doi: 10.3389/fneur.2018.00870. eCollection 2018.

6.

A Systematic Review and Meta-Analysis of Alpha Synuclein Auto-Antibodies in Parkinson's Disease.

Scott KM, Kouli A, Yeoh SL, Clatworthy MR, Williams-Gray CH.

Front Neurol. 2018 Oct 1;9:815. doi: 10.3389/fneur.2018.00815. eCollection 2018.

7.

The clinical heterogeneity of Parkinson's disease and its therapeutic implications.

Greenland JC, Williams-Gray CH, Barker RA.

Eur J Neurosci. 2019 Feb;49(3):328-338. doi: 10.1111/ejn.14094. Epub 2018 Oct 14.

PMID:
30059179
8.

The motor and cognitive features of Parkinson's disease in patients with concurrent Gaucher disease over 2 years: a case series.

Collins LM, Williams-Gray CH, Morris E, Deegan P, Cox TM, Barker RA.

J Neurol. 2018 Aug;265(8):1789-1794. doi: 10.1007/s00415-018-8908-6. Epub 2018 May 29.

9.

Abnormalities of age-related T cell senescence in Parkinson's disease.

Williams-Gray CH, Wijeyekoon RS, Scott KM, Hayat S, Barker RA, Jones JL.

J Neuroinflammation. 2018 May 28;15(1):166. doi: 10.1186/s12974-018-1206-5.

10.

Targeting Aged Astrocytes May Be a New Therapeutic Strategy in Parkinson's Disease.

Scott KM, Williams-Gray CH.

Mov Disord. 2018 May;33(5):758-759. doi: 10.1002/mds.27387. Epub 2018 Apr 6. No abstract available.

PMID:
29633419
11.

Parkinson disease: Defining PD subtypes - a step toward personalized management?

Williams-Gray CH, Barker RA.

Nat Rev Neurol. 2017 Aug;13(8):454-455. doi: 10.1038/nrneurol.2017.98. Epub 2017 Jul 7. No abstract available.

PMID:
28685759
12.

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.

Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR; HBS; CamPaIGN; PICNICS; PROPARK; PSG; DIGPD; PDBP.

Lancet Neurol. 2017 Aug;16(8):620-629. doi: 10.1016/S1474-4422(17)30122-9. Epub 2017 Jun 16. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

13.

The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward.

Lehericy S, Vaillancourt DE, Seppi K, Monchi O, Rektorova I, Antonini A, McKeown MJ, Masellis M, Berg D, Rowe JB, Lewis SJG, Williams-Gray CH, Tessitore A, Siebner HR; International Parkinson and Movement Disorder Society (IPMDS)-Neuroimaging Study Group.

Mov Disord. 2017 Apr;32(4):510-525. doi: 10.1002/mds.26968. Epub 2017 Mar 28. Review.

PMID:
28370449
14.

Stability of mild cognitive impairment in newly diagnosed Parkinson's disease.

Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH, Barker RA, Burn DJ; ICICLE-PD study group.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):648-652. doi: 10.1136/jnnp-2016-315099. Epub 2017 Mar 1.

15.

Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.

Liu G, Boot B, Locascio JJ, Jansen IE, Winder-Rhodes S, Eberly S, Elbaz A, Brice A, Ravina B, van Hilten JJ, Cormier-Dequaire F, Corvol JC, Barker RA, Heutink P, Marinus J, Williams-Gray CH, Scherzer CR; International Genetics of Parkinson Disease Progression (IGPP) Consortium.

Ann Neurol. 2016 Nov;80(5):674-685. doi: 10.1002/ana.24781.

16.

α-Synuclein pre-formed fibrils impair tight junction protein expression without affecting cerebral endothelial cell function.

Kuan WL, Bennett N, He X, Skepper JN, Martynyuk N, Wijeyekoon R, Moghe PV, Williams-Gray CH, Barker RA.

Exp Neurol. 2016 Nov;285(Pt A):72-81. doi: 10.1016/j.expneurol.2016.09.003. Epub 2016 Sep 12.

PMID:
27632900
17.

The Genetic Basis of Cognitive Impairment and Dementia in Parkinson's Disease.

Collins LM, Williams-Gray CH.

Front Psychiatry. 2016 May 20;7:89. doi: 10.3389/fpsyt.2016.00089. eCollection 2016. Review.

18.

Cognitive decline and quality of life in incident Parkinson's disease: The role of attention.

Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH, Barker RA, Collerton D, Taylor JP, Burn DJ; ICICLE-PD study group.

Parkinsonism Relat Disord. 2016 Jun;27:47-53. doi: 10.1016/j.parkreldis.2016.04.009. Epub 2016 Apr 11.

19.

Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data.

Mok KY, Sheerin U, Simón-Sánchez J, Salaka A, Chester L, Escott-Price V, Mantripragada K, Doherty KM, Noyce AJ, Mencacci NE, Lubbe SJ; International Parkinson's Disease Genomics Consortium (IPDGC), Williams-Gray CH, Barker RA, van Dijk KD, Berendse HW, Heutink P, Corvol JC, Cormier F, Lesage S, Brice A, Brockmann K, Schulte C, Gasser T, Foltynie T, Limousin P, Morrison KE, Clarke CE, Sawcer S, Warner TT, Lees AJ, Morris HR, Nalls MA, Singleton AB, Hardy J, Abramov AY, Plagnol V, Williams NM, Wood NW.

Lancet Neurol. 2016 May;15(6):585-96. doi: 10.1016/S1474-4422(16)00071-5. Epub 2016 Mar 24.

20.

Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).

Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans JR, Cummins GA, Duncan GW, Khoo TK, Burn DJ, Barker RA; ICICLE-PD study group.

Mov Disord. 2016 Jul;31(7):995-1003. doi: 10.1002/mds.26563. Epub 2016 Mar 21.

21.

Development and external validation of a prognostic model in newly diagnosed Parkinson disease.

Velseboer DC, de Bie RM, Wieske L, Evans JR, Mason SL, Foltynie T, Schmand B, de Haan RJ, Post B, Barker RA, Williams-Gray CH.

Neurology. 2016 Mar 15;86(11):986-93. doi: 10.1212/WNL.0000000000002437. Epub 2016 Feb 17.

22.

Comparative epidemiology of incident Parkinson's disease in Cambridgeshire, UK.

Evans JR, Cummins G, Breen DP, Foltynie T, Mason SL, Brayne CE, Williams-Gray CH, Barker RA.

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):1034-6. doi: 10.1136/jnnp-2015-312581. Epub 2016 Jan 22. No abstract available.

PMID:
26800710
23.

Review: The spectrum of clinical features seen with alpha synuclein pathology.

Barker RA, Williams-Gray CH.

Neuropathol Appl Neurobiol. 2016 Feb;42(1):6-19. doi: 10.1111/nan.12303. Review.

PMID:
26750431
24.

A new biomarker for Parkinson's disease?

Williams-Gray CH.

Mov Disord. 2016 Jan;31(1):42. doi: 10.1002/mds.26448. Epub 2015 Dec 21. No abstract available.

PMID:
26688186
25.

Which patients with Parkinson's disease participate in clinical trials? One centre's experiences with a new cell based therapy trial (TRANSEURO).

Moore SF, Guzman NV, Mason SL, Williams-Gray CH, Barker RA.

J Parkinsons Dis. 2014;4(4):671-6. doi: 10.3233/JPD-140432.

PMID:
25170676
26.

Mild cognitive impairment and Parkinson's disease--something to remember.

Barker RA, Williams-Gray CH.

J Parkinsons Dis. 2014;4(4):651-6. doi: 10.3233/JPD-140427. Review.

PMID:
25147139
27.

Putative cortical dopamine levels affect cortical recruitment during planning.

Fallon SJ, Hampshire A, Williams-Gray CH, Barker RA, Owen AM.

Neuropsychologia. 2013 Sep;51(11):2194-201. doi: 10.1016/j.neuropsychologia.2013.07.016. Epub 2013 Aug 1.

28.

The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort.

Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, Barker RA.

J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1258-64. doi: 10.1136/jnnp-2013-305277. Epub 2013 Jun 18.

PMID:
23781007
29.

Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease.

Hudson G, Nalls M, Evans JR, Breen DP, Winder-Rhodes S, Morrison KE, Morris HR, Williams-Gray CH, Barker RA, Singleton AB, Hardy J, Wood NE, Burn DJ, Chinnery PF.

Neurology. 2013 May 28;80(22):2042-8. doi: 10.1212/WNL.0b013e318294b434. Epub 2013 May 3.

30.

Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort.

Winder-Rhodes SE, Evans JR, Ban M, Mason SL, Williams-Gray CH, Foltynie T, Duran R, Mencacci NE, Sawcer SJ, Barker RA.

Brain. 2013 Feb;136(Pt 2):392-9. doi: 10.1093/brain/aws318.

PMID:
23413260
31.

The Addenbrooke's Cognitive Examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders.

Rittman T, Ghosh BC, McColgan P, Breen DP, Evans J, Williams-Gray CH, Barker RA, Rowe JB.

J Neurol Neurosurg Psychiatry. 2013 May;84(5):544-51. doi: 10.1136/jnnp-2012-303618. Epub 2013 Jan 8.

32.

Excessive daytime sleepiness and its risk factors in incident Parkinson's disease.

Breen DP, Williams-Gray CH, Mason SL, Foltynie T, Barker RA.

J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):233-4. doi: 10.1136/jnnp-2012-304097. Epub 2012 Nov 26. No abstract available.

PMID:
23184153
33.

Systematic review and UK-based study of PARK2 (parkin), PINK1, PARK7 (DJ-1) and LRRK2 in early-onset Parkinson's disease.

Kilarski LL, Pearson JP, Newsway V, Majounie E, Knipe MD, Misbahuddin A, Chinnery PF, Burn DJ, Clarke CE, Marion MH, Lewthwaite AJ, Nicholl DJ, Wood NW, Morrison KE, Williams-Gray CH, Evans JR, Sawcer SJ, Barker RA, Wickremaratchi MM, Ben-Shlomo Y, Williams NM, Morris HR.

Mov Disord. 2012 Oct;27(12):1522-9. doi: 10.1002/mds.25132. Epub 2012 Sep 6. Review.

PMID:
22956510
34.

Addenbrooke's Cognitive Examination-Revised for mild cognitive impairment in Parkinson's disease.

McColgan P, Evans JR, Breen DP, Mason SL, Barker RA, Williams-Gray CH.

Mov Disord. 2012 Aug;27(9):1173-7. doi: 10.1002/mds.25084. Epub 2012 Jun 25.

PMID:
22733390
35.

From molecule to clinic and community for neurodegeneration: research to bridge translational gaps.

Brayne C, Barker RA, Harold D, Ince PG, Savva GM, Williams J, Williams-Gray CH, Wharton SB.

J Alzheimers Dis. 2013;33 Suppl 1:S385-96. doi: 10.3233/JAD-2012-129006. Review.

PMID:
22647264
36.

Prefrontal dopamine levels determine the balance between cognitive stability and flexibility.

Fallon SJ, Williams-Gray CH, Barker RA, Owen AM, Hampshire A.

Cereb Cortex. 2013 Feb;23(2):361-9. doi: 10.1093/cercor/bhs025. Epub 2012 Feb 20.

PMID:
22351648
37.

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.

Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M.

Mov Disord. 2012 Mar;27(3):349-56. doi: 10.1002/mds.24893. Epub 2012 Jan 24. Review.

38.

Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome.

Winder-Rhodes SE, Garcia-Reitböck P, Ban M, Evans JR, Jacques TS, Kemppinen A, Foltynie T, Williams-Gray CH, Chinnery PF, Hudson G, Burn DJ, Allcock LM, Sawcer SJ, Barker RA, Spillantini MG.

Mov Disord. 2012 Feb;27(2):312-5. doi: 10.1002/mds.24029. Epub 2011 Nov 18.

PMID:
22102531
39.

The natural history of treated Parkinson's disease in an incident, community based cohort.

Evans JR, Mason SL, Williams-Gray CH, Foltynie T, Brayne C, Robbins TW, Barker RA.

J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1112-8. doi: 10.1136/jnnp.2011.240366. Epub 2011 May 18.

PMID:
21593513
40.

The factor structure of the UPDRS as an index of disease progression in Parkinson's disease.

Evans JR, Mason SL, Williams-Gray CH, Foltynie T, Trotter M, Barker RA.

J Parkinsons Dis. 2011;1(1):75-82. doi: 10.3233/JPD-2011-0002.

PMID:
23939258
41.

Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease.

Hoogland J, de Bie RM, Williams-Gray CH, Muslimović D, Schmand B, Post B.

Mov Disord. 2010 Nov 15;25(15):2550-4. doi: 10.1002/mds.23319.

PMID:
20878993
42.

Association of the human leucocyte antigen region with susceptibility to Parkinson's disease.

Saiki M, Baker A, Williams-Gray CH, Foltynie T, Goodman RS, Taylor CJ, Compston DA, Barker RA, Sawcer SJ, Goris A.

J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):890-1. doi: 10.1136/jnnp.2008.162883. Epub 2010 May 12.

PMID:
20462916
43.

The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort.

Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA.

Brain. 2009 Nov;132(Pt 11):2958-69. doi: 10.1093/brain/awp245. Epub 2009 Oct 7.

PMID:
19812213
44.

Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease.

Williams-Gray CH, Goris A, Saiki M, Foltynie T, Compston DA, Sawcer SJ, Barker RA.

J Neurol. 2009 Mar;256(3):493-8. doi: 10.1007/s00415-009-0119-8. Epub 2009 Mar 18.

PMID:
19308307
45.

BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.

Foltynie T, Cheeran B, Williams-Gray CH, Edwards MJ, Schneider SA, Weinberger D, Rothwell JC, Barker RA, Bhatia KP.

J Neurol Neurosurg Psychiatry. 2009 Feb;80(2):141-4. doi: 10.1136/jnnp.2008.154294. Epub 2008 Oct 31.

PMID:
18977816
46.

The val158met COMT polymorphism's effect on atrophy in healthy aging and Parkinson's disease.

Rowe JB, Hughes L, Williams-Gray CH, Bishop S, Fallon S, Barker RA, Owen AM.

Neurobiol Aging. 2010 Jun;31(6):1064-8. doi: 10.1016/j.neurobiolaging.2008.07.009. Epub 2008 Aug 27.

47.

Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition.

Rowe JB, Hughes L, Ghosh BC, Eckstein D, Williams-Gray CH, Fallon S, Barker RA, Owen AM.

Brain. 2008 Aug;131(Pt 8):2094-105. doi: 10.1093/brain/awn112. Epub 2008 Jun 24.

48.

The Cambridge Behavioural Inventory revised.

Wear HJ, Wedderburn CJ, Mioshi E, Williams-Gray CH, Mason SL, Barker RA, Hodges JR.

Dement Neuropsychol. 2008 Apr-Jun;2(2):102-107. doi: 10.1590/S1980-57642009DN20200005.

49.

Attentional control in Parkinson's disease is dependent on COMT val 158 met genotype.

Williams-Gray CH, Hampshire A, Barker RA, Owen AM.

Brain. 2008 Feb;131(Pt 2):397-408. doi: 10.1093/brain/awm313. Epub 2008 Jan 4.

PMID:
18178571
50.

Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease.

Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J, Ban M, Spillantini MG, Compston A, Burn DJ, Chinnery PF, Barker RA, Sawcer SJ.

Ann Neurol. 2007 Aug;62(2):145-53.

PMID:
17683088

Supplemental Content

Loading ...
Support Center